The Alzheimer’s Drug Discovery Foundation (ADDF) is the only public charity whose sole mission is to rapidly accelerate the discovery and development of drugs to prevent, treat and cure Alzheimer’s disease, related dementias and cognitive aging.

We raise and award funds to academic and biotechnology scientists conducting drug discovery research in this field.

ADDF uses a venture philanthropy model to bridge the worldwide funding gap between basic research and later-stage development, using any return on investment to support new research.

CHAIRMAN  ■  Leonard A. Lauder

The Lauder Family’s support of the Alzheimer’s Drug Discovery Foundation and its partner organization, The Institute for the Study of Aging, is based on a heart-felt belief that we can make an important contribution to developing drugs that will have a significant impact on this dreaded illness.

PRESIDENT  ■  Nancy Corzine

Having lost my mother to Alzheimer’s, I have painful, first-hand experience with the heartaches that will be avoided once effective drugs are introduced into the market. ADDF research funding, combined with our programs that bring scientists into productive partnerships, are the key to making tremendous strides. The innovative programs ADDF supports fill me with optimism.

FOUNDING EXECUTIVE DIRECTOR  ■  Howard Fillit, MD

Our venture philanthropy model is clearly enabling scientists to make progress in identifying novel Alzheimer’s drugs. In the next five years, I believe drugs now in the pipeline will become available for patients suffering from Alzheimer’s disease.
VENTURE PHILANTHROPY FUND  The Fund for Alzheimer’s Drug Discovery opened in January 2007 with $1.95 million in assets, including a $1 million capital commitment from the Aetna Foundation. During 2007, the Fund Board of Advisors approved six investments in biotechnology companies.

The Fund is distinctive in its approach to supporting ADDF’s mission. Modeled on a traditional venture capital fund, the Venture Philanthropy Fund supports promising biotechnology companies that need capital in the early and risky stages of drug discovery.

Contributors to the Venture Philanthropy Fund can designate a 501(c)(3) organization to receive a pro rata return on investment, if and when biotechnology companies supported through the Fund achieve contractual milestones.

PARTNERSHIPS  ADDF partnered with The Association for Frontotemporal Dementias (AFTD) to establish an award to fund scientists developing drugs to combat frontotemporal dementia. The ADDF/AFTD Frontotemporal Dementia Drug Discovery Program is also relevant to Alzheimer’s disease, since both frontotemporal dementia and Alzheimer’s share commonalities.

The ADDF/Elan Novel Approaches to Drug Discovery for Alzheimer’s Disease program, now in its third year, enables ADDF and Elan Pharmaceuticals, Inc. to pool resources and expertise. The collaboration will fund new therapies that effectively treat Alzheimer’s disease.

FUNDRAISING EFFORTS  ADDF’s inaugural Connoisseur’s Dinner: An Evening of Wine and Art, held at Sotheby’s in New York, raised more than $830,000. The evening included a private viewing of Impressionist and Modern art and an auction of exclusive wines and luxury travel packages.

To raise public awareness about drug discovery for Alzheimer’s disease and increase our constituent base, ADDF hosted Dine and Learn salons in Birmingham, Chicago, San Francisco, and Vail.

NETWORKING FOR SUCCESS  ADDF organizes two international scientific conferences yearly as part of our ongoing efforts to increase researchers’ knowledge about Alzheimer’s disease and the drug discovery process. The conferences promote networking to catalyze the exchange of ideas and foster alliances that accelerate the development of new treatments for AD.

Our Annual International Conference for Alzheimer’s Disease Drug Discovery, held in October, focuses on the discovery and development of drugs targeting Alzheimer’s disease and related dementias. The Drug Discovery for Neurodegeneration conference, held in February, is designed to educate scientists on the process of translating basic neuroscience research into innovative therapies.
We gratefully acknowledge the following 2007 contributing partners for their commitment. Through their generosity, we are able to advance our mission of supporting and accelerating drug discovery research for Alzheimer’s disease and related dementias.

$1,000 AND ABOVE
Estée Lauder Trust

$100,000 AND ABOVE
The Association for Frontotemporal Dementias

Mr. and Mrs. Gary Cooney

Elan Pharmaceuticals, Inc.

The Lauder Foundation, Leonard and Evelyn Lauder Fund

The Thomas H. and Jamen F. Lowder Foundation

Mr. and Mrs. Randal Sandler

Forest Research Institute, a division of Forest Laboratories, Inc.

Johnson & Johnson Pharmaceutical R&D, LLC

Jon & Susan Rostenthal Foundation

$50,000 AND ABOVE
Mr. and Mrs. Dominic Camera

The Chisholm Foundation

Ms. Nancy Corzine

Acumen Pharmaceuticals, Inc.

$10,000 AND ABOVE
Gerson and Barbara Bakar Philanthropic Fund

Mr. Robert E. Barnhill, Jr.

Robert & Renee Belfer Family Foundation

Howard B. Bernick Foundation

Ms. Carol Seabrook Boulanger

Mr. and Mrs. Nick Brown

Mr. and Mrs. A. Steven Crown

Dalio Family Foundation, Inc.

Eisai, Inc.

El Lilly and Company

Ronne and Donald Hess Foundation

Mr. and Mrs. Jim Katzman

The Estée Lauder Companies Inc.

Mr. and Mrs. Alan Maguire

Ortho-McNeil Neurologics, Inc.

Pfizer, Inc.

Mr. Thomas Quick

Mr. and Mrs. Daniel Roitman

Mr. and Mrs. William Ruprecht

sand-aventsis U.S., Inc.

Scherer-Blough

Diana and Richard C. Strauss Foundation

Mr. Thomas Tuft

Tuft Family Foundation

Mr. and Mrs. Cyrus Vance, Jr.

$5,000 AND ABOVE
Acumen Pharmaceuticals, Inc.

Ms. Isabelle Black

Mr. and Mrs. Thomas Curtin, Sr.

Edgewater Management, Inc.

Christopher B. Galvin Family Foundation

Gilder Foundation, Inc.

Mr. and Mrs. Miller Goree

Ms. Ann Marie Huebner and Mr. Ross Waller

Neurochem, Inc.

Seabrook Foundation

Ms. Amy Treitel

Harriet Weintraub & Partners, Inc.

Wine Spectator

$1,000 AND ABOVE
Acliera, Inc.

Mr. and Mrs. Steven Arriga

Mr. and Mrs. Weston Andress

Mr. and Mrs. Rand Araskog

Mr. and Mrs. Cory Baldwin

Ms. Anne Bassi

Dennis Bassio Boutique, Inc.

Bear Stearns Securities Corp.

Mr. and Mrs. Bruce Berger

Mr. and Mrs. Daniel Bernstein

Bernstein Family Foundation

Mr. and Mrs. Steven Benzin

BIOMOL International, LP

Ms. Dona Brinkman and Mr. Fuad Hadi

John and Jacelyn Buckingham Family Foundation

Matthew and Carolyn Buckingham Foundation

Mr. Robert Burke

Dr. Linda and Mr. Arthur Carter

Mr. and Mrs. John Cooney

Mr. Lloyd Constantine

Dr. Michele Copeland and

Dr. Jonathan Halperin

Ms. Cecé Cord and Dr. John Baldwin

Ms. Leslie Cornfeld

Ms. Laurel Cutler and Mr. Theodore Israel, Jr.

Mr. and Mrs. Thomas Daggett

Mr. and Mrs. Raymond Daloio

Ms. Lynette Dallas

Mr. and Mrs. Roberto de Guardiola

Mr. John Dempsey

Valerie-Charles Diker Fund, Inc.

The Honorable Robin Chandler Duke

Mr. and Mrs. Paul Earle

Ehrenkranz Family Foundation

Mr. Tony Ervin

Mr. and Mrs. Peter Eversky

Michael & Anne Falk Foundation

Mr. Jeffrey Ferraro

FHC Health Systems, Inc.

Mr. David Fischer

The Berry Friedberg and Charlotte Moss Family Foundation

Ms. Cynthia Friedman

Don and Janie Friend Family Philanthropic Fund

Mr. Richard Furman

Andrew Henry Gerhard Family Trust

Sonora and Charles Gilman, Jr. Foundation, Inc.

Albert Glickman Family Foundation

The Goodman Family Foundation

Mr. and Mrs. James Gorrie

Ms. Lida Greenberg and Mr. Michael Exstein

Vicki and Michael Gross Family Foundation, Inc.

Harman Family Foundation

Mr. and Mrs. Richard Hauserman

Mr. and Mrs. Stephen Haynes

Mr. and Mrs. David Heller

Ms. Melinda Helvelson

Mr. and Mrs. Lawrence Herbert

Mr. and Mrs. Roger Hertog

Caroline F. Hirsch Foundation

Mr. and Mrs. John Hughie

L & G Hume Charitable Account

Mr. and Mrs. Steven Hurowitz

Hurst Family Foundation

Ms. Ann Jackson

Jarai-Scheer Corporation

Mr. and Mrs. Harry Kamen

Dr. and Mrs. Wayne Killion, Jr.

Kornfeld Foundation

Mr. and Mrs. Peter Krulwicht

Lafayette 146, Inc.

Mr. Ronald Launder

Mr. and Mrs. Scott Lawlor

Mr. and Mrs. Laurence Leeds, Jr.

The Samuel J. & Ethel LeFrak Charitable Trust

Ms. Loida Lewis

Lindenbaum Family Charitable Trust

The David & Sonja Mack Foundation, Inc.

Earle I. Mack Foundation, Inc.

Mr. and Mrs. William Mahoney

Mr. and Mrs. Vincent Malan

Marriott International, Inc.

Mr. and Mrs. John May

William D. Mayer

Mr. and Mrs. William E. Mayer

Mr. and Mrs. Trace McCreary

Ms. Anna McDonnell

Mr. and Mrs. Gregor Medinger

Richard Meier Foundation

Mr. and Mrs. C.B. Miller

The Claire and Theodore Morse Foundation

Mr. Karthim K. Muhr

National Alzheimer’s Association

Mr. Jack Natter

Mr. and Mrs. Daniel Neidich

H. Nelson and Associates, LLC

Mr. and Mrs. Donald Newhouse

Johnson & Johnson Pharmaceutical R&D, LLC

Forest Laboratories, Inc.

Richard Meier Foundation

Mr. and Mrs. Gregor Medinger

Mr. and Mrs. Trace McCreary

Ms. Anna McDonnell

Mr. and Mrs. Gregor Medinger

Richard Meier Foundation

Mr. and Mrs. C.B. Miller

The Claire and Theodore Morse Foundation

Mr. Karthim K. Muhr

National Alzheimer’s Association

Mr. Jack Natter

Mr. and Mrs. Daniel Neidich

H. Nelson and Associates, LLC

Mr. and Mrs. Donald Newhouse

Johnson & Johnson Pharmaceutical R&D, LLC

Forest Laboratories, Inc.

Richard Meier Foundation

Mr. and Mrs. Gregor Medinger

Mr. and Mrs. Trace McCreary

Ms. Anna McDonnell

Mr. and Mrs. Gregor Medinger

Richard Meier Foundation

Mr. and Mrs. C.B. Miller

The Claire and Theodore Morse Foundation

Mr. Karthim K. Muhr

National Alzheimer’s Association

Mr. Jack Natter

Mr. and Mrs. Daniel Neidich

H. Nelson and Associates, LLC

Mr. and Mrs. Donald Newhouse

Johnson & Johnson Pharmaceutical R&D, LLC

Forest Laboratories, Inc.

Richard Meier Foundation

Mr. and Mrs. Gregor Medinger

Mr. and Mrs. Trace McCreary

Ms. Anna McDonnell

Mr. and Mrs. Gregor Medinger

Richard Meier Foundation

Mr. and Mrs. C.B. Miller

The Claire and Theodore Morse Foundation

Mr. Karthim K. Muhr

National Alzheimer’s Association

Mr. Jack Natter

Mr. and Mrs. Daniel Neidich

H. Nelson and Associates, LLC

Mr. and Mrs. Donald Newhouse

Johnson & Johnson Pharmaceutical R&D, LLC

Forest Laboratories, Inc.

Richard Meier Foundation

Mr. and Mrs. Gregor Medinger

Mr. and Mrs. Trace McCreary

Ms. Anna McDonnell

Mr. and Mrs. Gregor Medinger

Richard Meier Foundation

Mr. and Mrs. C.B. Miller

The Claire and Theodore Morse Foundation

Mr. Karthim K. Muhr

National Alzheimer’s Association

Mr. Jack Natter

Mr. and Mrs. Daniel Neidich

H. Nelson and Associates, LLC

Mr. and Mrs. Donald Newhouse

Johnson & Johnson Pharmaceutical R&D, LLC

Forest Laboratories, Inc.

Richard Meier Foundation

Mr. and Mrs. Gregor Medinger

Mr. and Mrs. Trace McCreary

Ms. Anna McDonnell

Mr. and Mrs. Gregor Medinger

Richard Meier Foundation

Mr. and Mrs. C.B. Miller

The Claire and Theodore Morse Foundation

Mr. Karthim K. Muhr

National Alzheimer’s Association

Mr. Jack Natter

Mr. and Mrs. Daniel Neidich

H. Nelson and Associates, LLC

Mr. and Mrs. Donald Newhouse

Johnson & Johnson Pharmaceutical R&D, LLC

Forest Laboratories, Inc.

Richard Meier Foundation

Mr. and Mrs. Gregor Medinger

Mr. and Mrs. Trace McCreary

Ms. Anna McDonnell

Mr. and Mrs. Gregor Medinger

Richard Meier Foundation

Mr. and Mrs. C.B. Miller

The Claire and Theodore Morse Foundation

Mr. Karthim K. Muhr

National Alzheimer’s Association

Mr. Jack Natter

Mr. and Mrs. Daniel Neidich

H. Nelson and Associates, LLC

Mr. and Mrs. Donald Newhouse

Johnson & Johnson Pharmaceutical R&D, LLC

Forest Laboratories, Inc.
ACADEMIC PROGRAMS

Daniel Alkon, MD
Blanchette Rockefeller Neurosciences Institute
A Peripheral Molecular Biomarker for Alzheimer’s Disease: Transgenic and Clinical Studies to Define CNS Pathophysiologic Significance
Award: $70,000

Ben Bahr, PhD
University of Connecticut
In Vitro Testing of New Lysosomal Modulatory Drugs for Reducing Tau Aggregates in a Hippocampal Slice Model
Award: $65,000

Larry Baum, PhD
The Chinese University of Hong Kong
Testing 17-AG for Treating Frontotemporal Dementia
Award: $50,000

Roberta Diaz Brinton, PhD
University of Southern California
Alsopregnanolone as a Neurogenic Factor for Recovery of Neurons in Alzheimer’s Disease
Award: $56,998

Siew Yeen Chai, PhD
Sloan-Kettering Institute
IRAP – Novel Target for the Development of Memory-Enhancing Agents
Award: $88,000

Gabriela Chiosis, PhD
University of Pennsylvania
Development of Hsp90 Inhibitors as Novel Therapeutics for AD
Award: $100,000

A. Claudio Cuello, MD, DSc, FRSC
McGill University
A Novel Combined Experimental Therapy in an Alzheimer’s Transgenic Model
Award: $100,000

Christos Davatzikos, PhD
University of Pennsylvania
Predicting Conversion From MCI to AD Via 4-Dimensional Pattern Analysis and Classification of ADNI Imaging Data
Award: $98,484

Nazneen Dewji, PhD
University of California, San Diego
Novel Therapeutic Approaches for the Treatment of Alzheimer’s Disease
Award: $75,000

Douglas Feinstein, PhD
University of Illinois
Regulation of Nephrin Expression by Noradrenaline and FFAR Agonists
Award: $90,000

Paul Gard, PhD
University of Brighton
Cognitive-Enhancing Effects of Angiotensin IV: An Investigation of Molecular Mechanisms
Award: $16,000

Shaila Handattu, PhD
University of Alabama at Birmingham
HDL Modulation, Inflammation and Alzheimer’s Disease
Award: $89,016

Louis B. Hersh, PhD
University of Kentucky
Nephrin and Peripheral Clearance of Amyloid Peptides
Award: $100,000

Anthony Koleske, PhD
Yale University Medical School
Inhibition of Rho Signaling to Prevent Dendritic and Synaptic Loss in Alzheimer’s Disease
Award: $100,000

Alan Kozikowski, PhD
University of Illinois at Chicago
Chromatin Remodelers for Recovery of Learning and Memory
Award: $100,000

Warren C. Ladiges, DVM, MS
University of Washington
ER Stress-Mediated Regulation of APP Proteolysis and Signaling
Award: $75,000

Iliya M. Letterov, MD, PhD
University of Pittsburgh
Identifying LXR Activators for Potential Treatment of Alzheimer’s Disease
Award: $150,000

Yung-Feng Liao, PhD
Academia Sinica
Genetic Modifiers of Gamma-Secretase-Mediated Cleavage of Amyloid Precursor Protein in Alzheimer’s Disease
Award: $50,000

Paul Lombroso, MD
Yale University Medical School
Screening for Inhibitors of STEP
Award: $100,000

Jose Luchsinger, MD, MPH
Columbia University
Pilot Trial of Memformin in the Prevention of Alzheimer’s Disease
Award: $100,000

James Malter, PhD
University of Wisconsin-Madison Medical School
Treatment of Alzheimer’s Disease with mGluR5 Inhibitor
Award: $96,427

Eva-Maria Mandelkow, MD, PhD
Max-Planck-Unit for Structural Molecular Biology
Models for AD Therapeutic Identification
Award: $200,000

Luciano D’Adamo, MD, PhD
FremeGenix, Inc.
Commercialization of BR12 Peptides for AD
Award: $100,000

Patricia Johnston, PhD
Cellumen, Inc.
Development of Cellular Systems Biology Models for AD Therapeutic Identification
Award: $200,000

Frank M. Longo, MD, PhD
PharmatrophiX
Inhibition of Alzheimer-Related Neurodegeneration by Small Molecule Neurotrophin Receptor Ligands
Award: $300,000

James G. Moe, PhD, MBA
Oligomirix, Inc.
Evaluation of Anti-Amyloid Compounds on Soluble Tau Oligomers, Synaptic Plasticity Inhibited by Tau, and Behavioral Deficits in a Tau P301L Mouse Model of Tauopathy
Award: $100,000

Manfred Windisch, PhD
Jawaharlal Nehru University
Development of New Drugs for Treating the Cognitive Deficits and Psychotic Symptoms of Alzheimer’s Disease
Award: $75,000

Raz Yirmiya, PhD
The Hebrew University of Jerusalem
The Role of Brain Interleukin-1 in Alzheimer’s Disease-Associated Memory Disturbances
Award: $40,000

Moussa B.H. Youdim, PhD
Technion – Israel Institute of Technology
Development and Molecular Mechanism of Neuroprotective Activity of Novel Bifunctional Cholinesterase-Monoamine Oxidase Inhibitor-Iron Chelators for the Treatment of Alzheimer’s Disease and Lewy Body Disease
Award: $120,000

BIOTECHNOLOGY PROGRAMS

Luciano D’Adamo, MD, PhD
FremeGenix, Inc.
Commercialization of BR12 Peptides for AD
Award: $100,000

Patricia Johnston, PhD
Cellumen, Inc.
Development of Cellular Systems Biology Models for AD Therapeutic Identification
Award: $200,000

Frank M. Longo, MD, PhD
PharmatrophiX
Inhibition of Alzheimer-Related Neurodegeneration by Small Molecule Neurotrophin Receptor Ligands
Award: $300,000

James G. Moe, PhD, MBA
Oligomirix, Inc.
Evaluation of Anti-Amyloid Compounds on Soluble Tau Oligomers, Synaptic Plasticity Inhibited by Tau, and Behavioral Deficits in a Tau P301L Mouse Model of Tauopathy
Award: $100,000

Manfred Windisch, PhD
Jawaharlal Nehru University
Development of New Drugs for Treating the Cognitive Deficits and Psychotic Symptoms of Alzheimer’s Disease
Award: $75,000

Raz Yirmiya, PhD
The Hebrew University of Jerusalem
The Role of Brain Interleukin-1 in Alzheimer’s Disease-Associated Memory Disturbances
Award: $40,000

Moussa B.H. Youdim, PhD
Technion – Israel Institute of Technology
Development and Molecular Mechanism of Neuroprotective Activity of Novel Bifunctional Cholinesterase-Monoamine Oxidase Inhibitor-Iron Chelators for the Treatment of Alzheimer’s Disease and Lewy Body Disease
Award: $120,000

CONFERENCES

Amos Korczyn, MD, MSc
Tel Aviv University
The Fifth International Congress on Vascular Dementia
Award: $2,500

Andrew Robertson, PhD
Keystone Symposia
Molecular Mechanisms of Neurodegeneration
Award: $2,500

Sally Shumaker, PhD
Wake Forest Health Sciences
11th Biennial Grayson Conference on Women’s Cognitive Health
Award: $2,500
The Alzheimer’s Drug Discovery Foundation (ADDF) is a public charity established in 2004 to expand upon the programs started by the Institute for the Study of Aging Inc. (ISOA), a private foundation founded by the Lauder family in 1998. ISOA provides crucial support for overhead and operational expenses, enabling ADDF to channel almost 80% of the revenue it raises to research programs.

During 2007, the ADDF raised more than $2.7 million to bring total funding for our first four years of operation to over $6 million.

ADDF in partnership with ISOA have awarded more than $33 million for over 240 research programs in 12 countries since 1998. In 2007, the ADDF and ISOA approved $4.5 million in grants to 44 research programs and 3 conferences worldwide. The total grant spending for 2007, including ongoing commitments, was $6.1 million.

Due to increasing demand for funds to support Alzheimer’s disease drug discovery research, ADDF and ISOA fund less than ten percent of the proposals received, leaving much valuable research unfunded.

The only way we can end the nightmare of Alzheimer’s disease is to collectively support scientists in their research efforts to develop new drugs. We encourage you to partner with us to conquer Alzheimer’s.

**BOARD OF DIRECTORS**

- **Co-Chairperson**
  - Leonard A. Lauder
- **Co-Chairperson**
  - Ronald S. Lauder
- **President**
  - Nancy Corzine
- **Executive Director**
  - Howard Fillit, MD
- **Members**
  - John Cooney
  - Jon Rotenstreich
  - Randal Sandler
  - Richard J. Schwartz
  - Cyrus Vance, Jr.

**STAFF**

- **Executive Director**
  - Howard Fillit, MD
- **COO and Managing Director**
  - Catherine Camera
- **Director of Scientific Affairs**
  - Antony Horton, PhD
- **Special Events Manager**
  - Sharon Becker
- **Executive Assistant**
  - David Di Vincenzo
- **Office Manager**
  - Frances Iliá
- **Grants Manager**
  - James Keller
- **Partnership Relations Manager**
  - Filomena Machleder
- **Development Associate**
  - Rachel Mante
- **Executive Assistant**
  - Kerry Walsh

**IMPACT OF FUNDING**

The overarching impact of ADDF and ISOA’s funding can be measured by:
- Millions of compounds screened
- Novel leads and new classes of drugs developed
- Scores of patents applied for and granted
- Licensing and partnership agreements with pharmaceutical companies
- Innovative therapies that have now advanced into clinical development

**THE GROWTH OF SUPPORT**

ADDF raised more than $2.7 million in 2007, almost seven times the amount raised in the first year.

<table>
<thead>
<tr>
<th>Year</th>
<th>(in millions)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2004</td>
<td>0.3</td>
</tr>
<tr>
<td>2005</td>
<td>1.0</td>
</tr>
<tr>
<td>2006</td>
<td>2.0</td>
</tr>
<tr>
<td>2007</td>
<td>3.0</td>
</tr>
</tbody>
</table>

Advancing drug discovery for Alzheimer’s disease through venture philanthropy